Leila Dardaei

3.3k total citations
13 papers, 627 citations indexed

About

Leila Dardaei is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Leila Dardaei has authored 13 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Leila Dardaei's work include Lung Cancer Treatments and Mutations (4 papers), Epigenetics and DNA Methylation (3 papers) and RNA modifications and cancer (2 papers). Leila Dardaei is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Epigenetics and DNA Methylation (3 papers) and RNA modifications and cancer (2 papers). Leila Dardaei collaborates with scholars based in United States, Italy and Iran. Leila Dardaei's co-authors include Francesco Blasi, Elena Longobardi, Satoshi Yoda, Alice T. Shaw, Luc Friboulet, Katherine R. Schultz, Ibiayi Dagogo‐Jack, Justin F. Gainor, Dmitry Penkov and Chiara Bruckmann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Cancer Research.

In The Last Decade

Leila Dardaei

13 papers receiving 625 citations

Peers

Leila Dardaei
Hideki Terai Japan
Anna Wurtz United States
Katherine R. Singleton United States
J. Baselga Spain
Rebecca Watters United States
Kaori Fujimoto-Ouchi United States
Christine To Canada
Nerissa Mendoza United States
Alessandra Capodanno Italy
Alex H. Ramos United States
Hideki Terai Japan
Leila Dardaei
Citations per year, relative to Leila Dardaei Leila Dardaei (= 1×) peers Hideki Terai

Countries citing papers authored by Leila Dardaei

Since Specialization
Citations

This map shows the geographic impact of Leila Dardaei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leila Dardaei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leila Dardaei more than expected).

Fields of papers citing papers by Leila Dardaei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leila Dardaei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leila Dardaei. The network helps show where Leila Dardaei may publish in the future.

Co-authorship network of co-authors of Leila Dardaei

This figure shows the co-authorship network connecting the top 25 collaborators of Leila Dardaei. A scholar is included among the top collaborators of Leila Dardaei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leila Dardaei. Leila Dardaei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Yoda, Satoshi, Leila Dardaei, Kylie Prutisto-Chang, et al.. (2018). Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation. Cancer Research. 78(13_Supplement). 4795–4795. 1 indexed citations
2.
Momeny, Majid, Ghazaleh Zarrinrad, Haniyeh Eyvani, et al.. (2017). Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Scientific Reports. 7(1). 45954–45954. 30 indexed citations
3.
Momeny, Majid, Ghazaleh Zarrinrad, Shahab Mirshahvaladi, et al.. (2017). Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Scientific Reports. 7(1). 44075–44075. 30 indexed citations
4.
Gainor, Justin F., Diane Tseng, Satoshi Yoda, et al.. (2017). Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer. JCO Precision Oncology. 2017(1). 1–13. 200 indexed citations
5.
Yoda, Satoshi, Leila Dardaei, Manrose Singh, et al.. (2017). Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib. Cancer Research. 77(13_Supplement). 3144–3144. 1 indexed citations
6.
Blasi, Francesco, Chiara Bruckmann, Dmitry Penkov, & Leila Dardaei. (2017). A tale of TALE, PREP1, PBX1, and MEIS1: Interconnections and competition in cancer. BioEssays. 39(5). 47 indexed citations
7.
Gainor, Justin F., Leila Dardaei, Satoshi Yoda, et al.. (2016). Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. European Journal of Cancer. 69. S138–S138. 119 indexed citations
8.
Dardaei, Leila, Dmitry Penkov, Lisa Mathiasen, et al.. (2015). Tumorigenesis by Meis1 overexpression is accompanied by a change of DNA target-sequence specificity which allows binding to the AP-1 element. Oncotarget. 6(28). 25175–25187. 12 indexed citations
9.
Dardaei, Leila, et al.. (2014). The Deficiency of Tumor Suppressor Prep1 Accelerates the Onset of Meis1- Hoxa9 Leukemogenesis. PLoS ONE. 9(5). e96711–e96711. 8 indexed citations
10.
Dardaei, Leila, Elena Longobardi, & Francesco Blasi. (2014). Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis. Proceedings of the National Academy of Sciences. 111(10). E896–905. 44 indexed citations
11.
Risolino, Maurizio, Francescopaolo Iavarone, Leila Dardaei, et al.. (2014). Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β–SMAD3 pathway in non-small cell lung adenocarcinoma. Proceedings of the National Academy of Sciences. 111(36). E3775–84. 82 indexed citations
12.
Iotti, Giorgio Antonio, Elena Longobardi, Leila Dardaei, et al.. (2011). Homeodomain transcription factor and tumor suppressor Prep1 is required to maintain genomic stability. Proceedings of the National Academy of Sciences. 108(29). E314–22. 32 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideki Terai Breakdown of academic impact, for papers by Anna Wurtz Breakdown of academic impact, for papers by Katherine R. Singleton Breakdown of academic impact, for papers by J. Baselga Breakdown of academic impact, for papers by Rebecca Watters Breakdown of academic impact, for papers by Kaori Fujimoto-Ouchi Breakdown of academic impact, for papers by Christine To Breakdown of academic impact, for papers by Nerissa Mendoza Breakdown of academic impact, for papers by Alessandra Capodanno Breakdown of academic impact, for papers by Alex H. Ramos
Rankless by CCL
2026